Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Neoplasms of the CNS

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 190 articles:
HTML format

Single Articles

    September 2020
  1. FERREIRA S, Foray C, Gatto A, Larcher M, et al
    AsiDNA is a radiosensitizer with no added toxicity in medulloblastoma pediatric models.
    Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-1729.
    PubMed     Abstract available

    August 2020
  2. ACCOMANDO WP, Rao AR, Hogan DJ, Newman AM, et al
    Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma.
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-0536.
    PubMed     Abstract available

  3. WILDES TJ, Dyson KA, Francis CP, Wummer BM, et al
    Immune escape after adoptive T cell therapy for malignant gliomas.
    Clin Cancer Res. 2020 Aug 11. pii: 1078-0432.CCR-20-1065.
    PubMed     Abstract available

    July 2020
  4. BATICH KA, Mitchell DA, Healy P, Herndon JE, et al
    Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.
    Clin Cancer Res. 2020 Jul 27. pii: 1078-0432.CCR-20-1082.
    PubMed     Abstract available

  5. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed     Abstract available

  6. YE Z, Price RL, Liu X, Lin J, et al
    Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0736.
    PubMed     Abstract available

    June 2020
  7. OTT M, Kassab C, Marisetty A, Hashimoto Y, et al
    Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy.
    Clin Cancer Res. 2020 Jun 30. pii: 1078-0432.CCR-19-4092.
    PubMed     Abstract available

  8. RAO G, Latha K, Ott M, Sabbagh A, et al
    Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells.
    Clin Cancer Res. 2020 Jun 18. pii: 1078-0432.CCR-19-4110.
    PubMed     Abstract available

  9. LADOMERSKY E, Zhai L, Lauing KL, Bell A, et al
    Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
    Clin Cancer Res. 2020 Jun 16. pii: 1078-0432.CCR-19-3874.
    PubMed     Abstract available

  10. KHASRAW M, Reardon DA, Weller M, Sampson JH, et al
    PD-1 inhibitors: Do they have a future in the treatment of glioblastoma?
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-1135.
    PubMed     Abstract available

  11. INDRACCOLO S, De Salvo GL, Verza M, Caccese M, et al
    Phosphorylated Acetyl-CoA Carboxylase is associated with clinical benefit with Regorafenib in relapsed glioblastoma: REGOMA Trial Biomarker Analysis.
    Clin Cancer Res. 2020 Jun 9. pii: 1078-0432.CCR-19-4055.
    PubMed     Abstract available

    May 2020
  12. SCHEETZ L, Kadiyala P, Sun X, Son S, et al
    Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-20-0341.
    PubMed     Abstract available

  13. KANE JR, Zhao J, Tsujiuchi T, Laffleur B, et al
    CD8(+) T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-3104.
    PubMed     Abstract available

  14. STRAGLIOTTO G, Pantalone MR, Rahbar A, Bartek J, et al
    Valganciclovir as add-on to standard therapy in glioblastoma patients.
    Clin Cancer Res. 2020 May 18. pii: 1078-0432.CCR-20-0369.
    PubMed     Abstract available

  15. BAGLEY SJ, Carpenter EL
    Plasma cfDNA in Glioblastoma-Response.
    Clin Cancer Res. 2020;26:2276.

  16. TAKAYASU T, Esquenazi Y, Ballester LY
    Plasma cfDNA in Glioblastoma-Letter.
    Clin Cancer Res. 2020;26:2275.

    April 2020
  17. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
    PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
    Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
    PubMed     Abstract available

  18. MENDEZ F, Kadiyala P, Nunez FJ, Carney S, et al
    Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK/Flt3L) gene therapy in a mouse model of high grade brainstem glioma.
    Clin Cancer Res. 2020 Apr 24. pii: 1078-0432.CCR-19-3714.
    PubMed     Abstract available

  19. LEE JH, Menzies AM, Carlino MS, McEvoy AC, et al
    Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3926.
    PubMed     Abstract available

  20. WEATHERS SP, Penas-Prado M, Pei BL, Ling X, et al
    Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-20-0176.
    PubMed     Abstract available

  21. LAWLER SE, Chiocca EA, Cook CH
    Cytomegalovirus encephalopathy during brain tumor irradiation.
    Clin Cancer Res. 2020 Apr 10. pii: 1078-0432.CCR-20-0646.
    PubMed     Abstract available

  22. ELLINGSON BM, Yao J, Raymond C, Nathanson DA, et al
    Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in patients with recurrent high-grade glioma.
    Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-3817.
    PubMed     Abstract available

    March 2020
  23. MEEL MH, de Gooijer MC, Metselaar DS, Sewing ACP, et al
    Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.
    Clin Cancer Res. 2020 Mar 12. pii: 1078-0432.CCR-19-3538.
    PubMed     Abstract available

  24. OTANI Y, Yoo JY, Chao S, Liu J, et al
    Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition.
    Clin Cancer Res. 2020 Mar 5. pii: 1078-0432.CCR-19-3420.
    PubMed     Abstract available

  25. KINSLOW CJ, Canoll P, Cheng SK, Wang TJC, et al
    Misclassification of Diffuse Gliomas-Letter.
    Clin Cancer Res. 2020;26:1198.

    February 2020
  26. BEIG N, Bera K, Prasanna P, Antunes J, et al
    Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma.
    Clin Cancer Res. 2020 Feb 20. pii: 1078-0432.CCR-19-2556.
    PubMed     Abstract available

  27. PIROVANO G, Jannetti SA, Carter LM, Sadique A, et al
    Targeted brain tumor radiotherapy using an Auger emitter.
    Clin Cancer Res. 2020 Feb 17. pii: 1078-0432.CCR-19-2440.
    PubMed     Abstract available

  28. DIRKS PB, Gilbert MR, Holland EC, Maher EA, et al
    Translating basic science discoveries into improved outcomes for glioblastoma.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3924.
    PubMed     Abstract available

  29. WICK W, Wagener RJ
    Not yet another negative trial - ReACTing on recent glioblastoma trials!
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-4032.
    PubMed     Abstract available

  30. REARDON DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, et al
    Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-18-1140.
    PubMed     Abstract available

  31. ZHANG IY, Zhou H, Liu H, Zhang L, et al
    Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-19-2520.
    PubMed     Abstract available

  32. TANG B, Guo ZS, Bartlett DL, Yan DZ, et al
    Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-18-3626.
    PubMed     Abstract available

  33. PASSARO C, Alayo Q, DeLaura I, McNulty J, et al
    Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
    Clin Cancer Res. 2020;26:758.

    January 2020
  34. MOHME M, Maire CL, Geumann U, Schliffke S, et al
    Local intracerebral immunomodulation using interleukin-expressing mesenchymal stem cells in glioblastoma.
    Clin Cancer Res. 2020 Jan 27. pii: 1078-0432.CCR-19-0803.
    PubMed     Abstract available

  35. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed     Abstract available

  36. GRAILLON T, Sanson M, Campello C, Idbaih A, et al
    Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-2109.
    PubMed     Abstract available

  37. NASSIRI F, Taslimi S, Wang JZ, Badhiwala JH, et al
    Determining the optimal adjuvant therapy for improving survival in elderly patients with glioblastoma: a systematic review and meta-analysis.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-3359.
    PubMed     Abstract available

  38. POCHA K, Mock A, Rapp C, Dettling S, et al
    Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
    PubMed     Abstract available

  39. WEN PY, Cloughesy TF, Olivero AG, Morrissey KM, et al
    First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2808.
    PubMed     Abstract available

  40. RODRIGUEZ GUTIERREZ D, Jones C, Varlet P, Mackay A, et al
    Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-3154.
    PubMed     Abstract available

  41. TU Y, Chen Z, Zhao P, Sun G, et al
    Smoothened promotes glioblastoma radiation resistance via activating USP3-mediated Claspin deubiquitination.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-1515.
    PubMed     Abstract available

  42. HIGUCHI F, Nagashima H, Ning J, Koerner MVA, et al
    Restoration of Temozolomide Sensitivity by Poly(ADP-Ribose) Polymerase inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-2000.
    PubMed     Abstract available

    December 2019
  43. WORONIECKA KI, Rhodin KE, Dechant CA, Waibl Polania J, et al
    4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Clin Cancer Res. 2019 Dec 23. pii: 1078-0432.CCR-19-1068.
    PubMed     Abstract available

  44. WU S, Gao F, Zheng S, Zhang C, et al
    EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma.
    Clin Cancer Res. 2019 Dec 18. pii: 1078-0432.CCR-19-2549.
    PubMed     Abstract available

  45. VAUBEL RA, Tian S, Remonde D, Schroeder MA, et al
    Genomic and phenotypic characterization of a broad panel of patient derived xenografts reflects the diversity of glioblastoma.
    Clin Cancer Res. 2019 Dec 18. pii: 1078-0432.CCR-19-0909.
    PubMed     Abstract available

  46. ZHANG DY, Dmello C, Chen L, Arrieta VA, et al
    Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-2182.
    PubMed     Abstract available

  47. HARGRAVE DR, Bouffet E, Tabori U, Broniscer A, et al
    Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.
    Clin Cancer Res. 2019 Dec 6. pii: 1078-0432.CCR-19-2177.
    PubMed     Abstract available

  48. CAMPAGNE O, Zhong B, Nair S, Lin T, et al
    Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-2685.
    PubMed     Abstract available

    October 2019
  49. BAGLEY S, Nabavizadeh SA, Mays J, Till JE, et al
    Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma - a pilot prospective study.
    Clin Cancer Res. 2019 Oct 30. pii: 1078-0432.CCR-19-2533.
    PubMed     Abstract available

  50. PARADA CA, Osbun JW, Busald T, Karasozen Y, et al
    Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals Rb1 signaling as a Novel Mediator and Biomarker.
    Clin Cancer Res. 2019 Oct 15. pii: 1078-0432.CCR-18-0641.
    PubMed     Abstract available

    September 2019
  51. GERSTNER E, Emblem KE, Chang K, Vakulenko-Lagun B, et al
    Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1739.
    PubMed     Abstract available

  52. VAN DER VOORT SR, Incekara F, Wijnenga MM, Kapsas G, et al
    Predicting the 1p/19q co-deletion status of presumed low grade glioma with an externally validated machine learning algorithm.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1127.
    PubMed     Abstract available

  53. SHARIFI Z, Abdulkarim B, Meehan B, Rak J, et al
    Antitumor Activity of a Binary EGFR/DNA Targeting Strategy Overcomes Resistance of Glioblastoma Stem cells to Temozolomide.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-19-0955.
    PubMed     Abstract available

  54. THOMAS RP, Nagpal S, Iv M, Soltys SG, et al
    Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
    Clin Cancer Res. 2019 Sep 19. pii: 1078-0432.CCR-19-1421.
    PubMed     Abstract available

  55. PAPACHRISTODOULOU A, Silginer M, Weller M, Schneider H, et al
    Therapeutic targeting of TGF-beta ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas.
    Clin Cancer Res. 2019 Sep 17. pii: 1078-0432.CCR-17-3024.
    PubMed     Abstract available

  56. JUTHANI R, Madajewski B, Yoo B, Zhang L, et al
    Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1834.
    PubMed     Abstract available

  57. CHAUVIN C, Joalland N, Perroteau J, Jarry U, et al
    NKG2D controls natural reactivity of Vgamma9Vdelta2 T lymphocytes against mesenchymal glioblastoma cells.
    Clin Cancer Res. 2019 Sep 10. pii: 1078-0432.CCR-19-0375.
    PubMed     Abstract available

  58. JI J, Xu R, Ding K, Bao G, et al
    Long noncoding RNA SChLAP1 forms a growth promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-kappaB signaling.
    Clin Cancer Res. 2019 Sep 6. pii: 1078-0432.CCR-19-0747.
    PubMed     Abstract available

  59. WERBROUCK C, Evangelista CCS, Lobon-Iglesias MJ, Barret E, et al
    TP53 pathway alterations drive radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-0126.
    PubMed     Abstract available

  60. LI J, Xue Y, Wenger A, Sun Y, et al
    Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-0299.
    PubMed     Abstract available

    August 2019
  61. JIANG H, Shin DH, Nguyen TT, Fueyo J, et al
    Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Clin Cancer Res. 2019 Aug 27. pii: 1078-0432.CCR-19-0405.
    PubMed     Abstract available

  62. BODEKER KL, Allen BG, Smith MC, Monga V, et al
    First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma.
    Clin Cancer Res. 2019 Aug 19. pii: 1078-0432.CCR-19-0594.
    PubMed     Abstract available

    July 2019
  63. WEN PY, Reardon DA, Armstrong TS, Phuphanich S, et al
    A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma.
    Clin Cancer Res. 2019 Jul 18. pii: 1078-0432.CCR-19-0261.
    PubMed     Abstract available

  64. JUAREZ-CHAMBI RM, Kut C, Rico-Jimenez JJ, Chaichana KL, et al
    AI-Assisted In Situ Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography.
    Clin Cancer Res. 2019 Jul 17. pii: 1078-0432.CCR-19-0854.
    PubMed     Abstract available

  65. YANG ZJ, Du F, Yuelling LW, Lee EH, et al
    Leukotriene synthesis is critical for medulloblastoma progression.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-18-3549.
    PubMed     Abstract available

  66. TIEN AC, Li J, Bao X, DeRogatis A, et al
    A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0133.
    PubMed     Abstract available

  67. JONSSON P, Lin AL, Young RJ, DiStefano NM, et al
    Genomic correlates of disease progression and treatment response in prospectively characterized gliomas.
    Clin Cancer Res. 2019 Jul 1. pii: 1078-0432.CCR-19-0032.
    PubMed     Abstract available

    June 2019
  68. RAPP C, Dettling S, Liu F, Ull AT, et al
    Cytotoxic T-cells and their activation status are independent prognostic markers in meningiomas.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-0389.
    PubMed     Abstract available

  69. KATAGI H, Louis N, Unruh D, Sasaki T, et al
    Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3890.
    PubMed     Abstract available

  70. FECCI PE, Champion CD, Hoj J, McKernan C, et al
    The Evolving Modern Management of Brain Metastasis.
    Clin Cancer Res. 2019 Jun 18. pii: 1078-0432.CCR-18-1624.
    PubMed     Abstract available

    May 2019
  71. SMITH SJ, Tyler B, Gould TWA, Veal GJ, et al
    Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3850.
    PubMed     Abstract available

    April 2019
  72. MORIKAWA A, de Stanchina E, Pentsova E, Kemeny MM, et al
    Phase I study of intermittent high dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-3502.
    PubMed     Abstract available

    March 2019
  73. IDBAIH A, Canney M, Belin L, Desseaux C, et al
    Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2019 Mar 19. pii: 1078-0432.CCR-18-3643.
    PubMed     Abstract available

  74. LI H, Li J, Chen L, Qi S, et al
    HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma.
    Clin Cancer Res. 2019 Mar 12. pii: 1078-0432.CCR-18-3791.
    PubMed     Abstract available

  75. LAMANO JB, Lamano JB, Li YD, DiDomenico JD, et al
    Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-2402.
    PubMed     Abstract available

    February 2019
  76. TOMASZEWSKI W, Sanchez-Perez L, Gajewski TF, Sampson JH, et al
    Brain Tumor Micro-environment and Host State - Implications for Immunotherapy.
    Clin Cancer Res. 2019 Feb 25. pii: 1078-0432.CCR-18-1627.
    PubMed     Abstract available

  77. LASSMAN AB, Roberts-Rapp LA, Sokolova I, Song M, et al
    Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3034.
    PubMed     Abstract available

  78. HALL PE, Lewis R, Syed N, Shaffer R, et al
    A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3729.
    PubMed     Abstract available

  79. IPPEN FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, et al
    The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-3049.
    PubMed     Abstract available

  80. ZHANG Q, Zhang Y, Chen Y, Qian J, et al
    A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-2548.
    PubMed     Abstract available

  81. SIM HW, Nejad R, Zhang W, Nassiri F, et al
    Tissue 2-hydroxyglutarate as a biomarker for isocitrate dehydrogenase (IDH) mutations in gliomas.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-3205.
    PubMed     Abstract available

    January 2019
  82. INDIRA CHANDRAN V, Welinder C, Mansson AS, Offer S, et al
    Ultrasensitive immunoprofiling of plasma extracellular vesicles identifies syndecan-1 as a potential tool for minimally invasive diagnosis of glioma.
    Clin Cancer Res. 2019 Jan 24. pii: 1078-0432.CCR-18-2946.
    PubMed     Abstract available

  83. FINK MA, Paland H, Herzog S, Grube M, et al
    L-Carnitine Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2380.
    PubMed     Abstract available

  84. YUN J, Hong MH, Kim SY, Park CW, et al
    YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2906.
    PubMed     Abstract available

  85. PARK J, Kwon M, Kim KH, Kim TS, et al
    Immune Checkpoint Inhibitor-Induced Reinvigoration of Tumor-Infiltrating CD8(+) T Cells is Determined by Their Differentiation Status in Glioblastoma.
    Clin Cancer Res. 2019 Jan 18. pii: 1078-0432.CCR-18-2564.
    PubMed     Abstract available

  86. MAJZNER RG, Theruvath JL, Nellan A, Heitzeneder S, et al
    CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Clin Cancer Res. 2019 Jan 17. pii: 1078-0432.CCR-18-0432.
    PubMed     Abstract available

  87. BERGEN ES, Berghoff AS, Medjedovic M, Rudas M, et al
    Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-1968.
    PubMed     Abstract available

  88. CHENG VWT, Soto MS, Khrapitchev AA, Perez-Balderas F, et al
    VCAM-1-targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors.
    Clin Cancer Res. 2019;25:533-543.
    PubMed     Abstract available

  89. IORGULESCU JB, Torre M, Harary M, Smith TR, et al
    The Misclassification of Diffuse Gliomas: Rates and Outcomes.
    Clin Cancer Res. 2019 Jan 11. pii: 1078-0432.CCR-18-3101.
    PubMed     Abstract available

    December 2018
  90. HURVITZ SA, O'Shaughnessy J, Mason G, Yardley D, et al
    Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs.
    Clin Cancer Res. 2018 Dec 28. pii: 1078-0432.CCR-18-2366.
    PubMed     Abstract available

  91. INDRACCOLO S, Lombardi G, Fassan M, Pasqualini L, et al
    Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma.
    Clin Cancer Res. 2018 Dec 4. pii: 1078-0432.CCR-18-1892.
    PubMed     Abstract available

  92. HEGI ME, Genbrugge E, Gorlia T, Stupp R, et al
    MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials.
    Clin Cancer Res. 2018 Dec 4. pii: 1078-0432.CCR-18-3181.
    PubMed     Abstract available

    November 2018
  93. DAVIDSON TB, Lee AH, Hsu M, Sedighim S, et al
    Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation.
    Clin Cancer Res. 2018 Nov 29. pii: 1078-0432.CCR-18-1176.
    PubMed     Abstract available

  94. THULBORN KR, Lu A, Atkinson IC, Pauliah M, et al
    Residual Tumor Volume, Cell Volume Fraction and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR imaging.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-2079.
    PubMed     Abstract available

  95. ROBBINS DJ, Rodriguez-Blanco J, Li B, Shen C, et al
    A CK1alpha activator penetrates the brain, and shows efficacy against drug-resistant metastatic medulloblastoma.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-1319.
    PubMed     Abstract available

  96. CHOI BD, Maus MV, June CH, Sampson JH, et al
    ----Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Clin Cancer Res. 2018 Nov 16. pii: 1078-0432.CCR-18-1625.
    PubMed     Abstract available

  97. SPINO M, Kurz SC, Chiriboga L, Serrano J, et al
    Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-2312.
    PubMed     Abstract available

    October 2018
  98. JIANG S, Eberhart CG, Lim M, Heo HY, et al
    Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy.
    Clin Cancer Res. 2018 Oct 26. pii: 1078-0432.CCR-18-1233.
    PubMed     Abstract available

  99. PANDITHARATNA E, Kilburn LB, Aboian MS, Kambhampati M, et al
    Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1345.
    PubMed     Abstract available

  100. AGNIHOTRI S, Mansouri S, Burrell K, Li M, et al
    Ketoconazole and Posaconazole Selectively Target HK2 Expressing Glioblastoma Cells.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1854.
    PubMed     Abstract available

  101. OSTI D, Del Bene M, Rappa G, Santos M, et al
    Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.
    Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-18-1941.
    PubMed     Abstract available

  102. PASSARO C, Alayo Q, DeLaura I, McNulty JJ, et al
    Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2311.
    PubMed     Abstract available

  103. BERBERICH A, Kessler T, Thome CM, Pusch S, et al
    Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-1580.
    PubMed     Abstract available

    September 2018
  104. UNRUH D, Mirkov S, Wray B, Drumm M, et al
    Methylation-dependent Tissue Factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas.
    Clin Cancer Res. 2018 Sep 28. pii: 1078-0432.CCR-18-1222.
    PubMed     Abstract available

  105. CRUICKSHANKS N, Zhang Y, Hine S, Gibert M, et al
    Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0926.
    PubMed     Abstract available

  106. WAHL DR, Lawrence TS
    No sugar added: A new strategy to inhibit glioblastoma receptor tyrosine kinases.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-2113.
    PubMed     Abstract available

    August 2018
  107. DAVARE MA, Henderson JJ, Agarwal A, Wagner JP, et al
    Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma.
    Clin Cancer Res. 2018 Aug 31. pii: 1078-0432.CCR-18-1052.
    PubMed     Abstract available

  108. BLAKELEY JO, Grossman SA, Chi AS, Mikkelsen T, et al
    Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-0110.
    PubMed     Abstract available

    July 2018
  109. MEEL MH, de Gooijer MC, Guillen Navarro M, Waranecki P, et al
    MELK inhibition in Diffuse Intrinsic Pontine Glioma.
    Clin Cancer Res. 2018 Jul 30. pii: 1078-0432.CCR-18-0924.
    PubMed     Abstract available

  110. ZINN PO, Singh SK, Kotrotsou A, Hassan I, et al
    A co-clinical radiogenomic validation study - Conserved magnetic resonance radiomic appearance of Periostin expressing Glioblastoma in patients and xenograft models.
    Clin Cancer Res. 2018 Jul 27. pii: 1078-0432.CCR-17-3420.
    PubMed     Abstract available

  111. ISHIDA CT, Zhang Y, Bianchetti E, Shu C, et al
    Metabolic Reprogramming by Dual AKT/ERK Inhibition Through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-1040.
    PubMed     Abstract available

  112. ZHANG L, Sorensen M, Kristensen BW, Reifenberger G, et al
    The oncometabolite D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas that inhibits both complement and T cells.
    Clin Cancer Res. 2018 Jul 13. pii: 1078-0432.CCR-17-3855.
    PubMed     Abstract available

  113. BARO M, Lopez Sambrooks C, Quijano A, Saltzman WM, et al
    Oligosaccharyltransferase inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.
    Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0792.
    PubMed     Abstract available

    June 2018
  114. LEE EQ, Duda DG, Muzikansky A, Gerstner E, et al
    Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-18-1025.
    PubMed     Abstract available

  115. JURATLI TA, Stasik S, Zolal A, Schuster C, et al
    TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas - a pilot prospective study.
    Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-3717.
    PubMed     Abstract available

  116. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Abstract available

  117. BUERKI RA, Chheda ZS, Okada H
    Immunotherapy of Primary Brain Tumors: Facts and Hopes.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-17-2769.
    PubMed     Abstract available

    May 2018
  118. NODA M, Okayama H, Tachibana K, Sakamoto W, et al
    Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-17-3533.
    PubMed     Abstract available

    Targeted Therapies for Brain Tumors: Will They Ever Deliver?
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-0855.
    PubMed     Abstract available

  120. SANAI N, Li J, Boerner J, Stark K, et al
    Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-17-3348.
    PubMed     Abstract available

  121. LU CF, Hsu FT, Hsieh KL, Kao YJ, et al
    Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.
    Clin Cancer Res. 2018 May 22. pii: 1078-0432.CCR-17-3445.
    PubMed     Abstract available

  122. ZHANG Y, Ishida CT, Ishida W, Lo SL, et al
    Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and elicits Synthetic Lethality in Glioblastoma.
    Clin Cancer Res. 2018 May 15. pii: 1078-0432.CCR-18-0260.
    PubMed     Abstract available

    April 2018
  123. WILDES TJ, Grippin A, Dyson KA, Wummer BM, et al
    Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for malignant glioma.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-3061.
    PubMed     Abstract available

  124. GEDEON PC, Schaller TH, Chitneni SK, Choi BD, et al
    A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma.
    Clin Cancer Res. 2018 Apr 27. pii: 1078-0432.CCR-17-0126.
    PubMed     Abstract available

  125. KESARWANI P, Prabhu A, Kant S, Kumar P, et al
    Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0041.
    PubMed     Abstract available

  126. JACKSON CM, Lim M
    Immunotherapy for glioblastoma: playing chess, not checkers.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0491.
    PubMed     Abstract available

  127. MARTINEZ-RICARTE F, Mayor R, Martinez-Saez E, Rubio-Perez C, et al
    Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3800.
    PubMed     Abstract available

    March 2018
  128. SAHA D, Wakimoto H, Peters CW, Antoszczyk SJ, et al
    Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1717.
    PubMed     Abstract available

  129. WORONIECKA KI, Rhodin KE, Chongsathidkiet P, Keith KA, et al
    T-Cell Dysfunction in Glioblastoma: Applying a New Framework.
    Clin Cancer Res. 2018 Mar 28. pii: 1078-0432.CCR-18-0047.
    PubMed     Abstract available

  130. DETTLING S, Stamova S, Warta R, Schnolzer M, et al
    Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-1839.
    PubMed     Abstract available

  131. NAKASHIMA H, Nguyen T, Kasai K, Passaro C, et al
    Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma.
    Clin Cancer Res. 2018 Mar 6. pii: 1078-0432.CCR-17-2954.
    PubMed     Abstract available

  132. LADOMERSKY E, Zhai L, Lenzen A, Lauing KL, et al
    IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3573.
    PubMed     Abstract available

    February 2018
  133. NISHIYAMA A, Yamada T, Kita K, Wang R, et al
    Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-1623.
    PubMed     Abstract available

  134. LI XN, Kogiso M, Qi L, Braun FK, et al
    Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-2256.
    PubMed     Abstract available

  135. MOHME M, Schliffke S, Maire CL, Runger A, et al
    Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Clin Cancer Res. 2018 Feb 14. pii: 1078-0432.CCR-17-2617.
    PubMed     Abstract available

  136. HOLLON TC, Orringer DA
    Shedding light on IDH1 mutation in gliomas.
    Clin Cancer Res. 2018 Feb 13. pii: 1078-0432.CCR-18-0011.
    PubMed     Abstract available

  137. WORONIECKA K, Chongsathidkiet P, Rhodin KE, Kemeny HR, et al
    T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma.
    Clin Cancer Res. 2018 Feb 7. pii: 1078-0432.CCR-17-1846.
    PubMed     Abstract available

  138. GORDON RE, Zhang L, Peri S, Kuo YM, et al
    Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2923.
    PubMed     Abstract available

  139. KABRAJI S, Ni J, Lin N, Xie S, et al
    Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3351.
    PubMed     Abstract available

    January 2018
  140. GOMEZ S, Garrido-Garcia A, Garcia-Gerique L, Lemos I, et al
    A novel method for rapid molecular subgrouping of medulloblastoma.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-2243.
    PubMed     Abstract available

  141. NIMMERVOLL B, Boulos N, Bianski BM, Dapper J, et al
    Establishing A Preclinical Multidisciplinary Board for Brain Tumors.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2168.
    PubMed     Abstract available

    December 2017
  142. PAL J, Patil V, Kumar A, Kaur K, et al
    Loss-of-function mutations in Calcitonin receptor (CALCR) identify highly aggressive glioblastoma with poor outcome.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1901.
    PubMed     Abstract available

  143. UCKERMANN O, Juratli TA, Galli R, Conde M, et al
    Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
    Clin Cancer Res. 2017 Dec 19. pii: 1078-0432.CCR-17-1795.
    PubMed     Abstract available

  144. SU YT, Chen R, Wang H, Song H, et al
    Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Clin Cancer Res. 2017 Dec 18. pii: 1078-0432.CCR-17-2032.
    PubMed     Abstract available

  145. JIN X, Jin X, Kim LJY, Dixit D, et al
    Inhibition of ID1-BMPR2 intrinsic signaling sensitizes glioma stem cells to differentiation therapy.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1529.
    PubMed     Abstract available

    November 2017
  146. CHANG K, Bai HX, Zhou H, Su C, et al
    Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2236.2017.
    PubMed     Abstract available

  147. WEISS T, Schneider H, Silginer M, Steinle A, et al
    NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma.
    Clin Cancer Res. 2017 Nov 21. pii: clincanres.1766.2017.
    PubMed     Abstract available

  148. MIGLIORINI D, Dietrich PY, Stupp R, Linette GP, et al
    CAR-T cell Therapies in Glioblastoma: a first look.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.2871.2017.
    PubMed     Abstract available

  149. NANDHU MS, Behera P, Bhaskaran V, Longo SL, et al
    Development of a function-blocking antibody against fibulin-3 as targeted reagent for glioblastoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1628.2017.
    PubMed     Abstract available

  150. CHEN Q, Cai J, Wang Q, Wang Y, et al
    Long non-coding RNA NEAT1, regulated by the EGFR pathway, contributes to glioblastoma progression through the WNT/beta-Catenin pathway by scaffolding EZH2.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0605.2017.
    PubMed     Abstract available

  151. WICK W, Kessler T
    Drug repositioning meets precision in glioblastoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.2989.2017.
    PubMed     Abstract available

    October 2017
  152. BYRON SA, Tran NL, Halperin RF, Phillips JJ, et al
    Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.
    Clin Cancer Res. 2017 Oct 26. pii: clincanres.0963.2017.
    PubMed     Abstract available

  153. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Abstract available

  154. FAN Y, Zhu X, Xu Y, Lu X, et al
    Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
    PubMed     Abstract available

  155. ACERBI F, Broggi M, Schebesch KM, Hohne J, et al
    Fluorescein-guided surgery for resection of high-grade gliomas: A multicentric prospective phase II study (FLUOGLIO).
    Clin Cancer Res. 2017 Oct 10. pii: clincanres.1184.2017.
    PubMed     Abstract available

    September 2017
  156. AVRIL T, Etcheverry A, Pineau R, Obacz J, et al
    CD90 expression controls migration and predicts dasatinib response in glioblastoma.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1549.2017.
    PubMed     Abstract available

  157. LI J, Wu J, Bao X, Honea N, et al
    Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients using an IVIVE-PBPK Modeling Approach.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.0983.2017.
    PubMed     Abstract available

  158. MULLER-GREVEN GM, Carlin C, Burgett ME, Ahluwalia MS, et al
    Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0249.2017.
    PubMed     Abstract available

  159. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-beta in glioblastomas.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0077.2017.
    PubMed     Abstract available

    August 2017
  160. FELSBERG J, Hentschel B, Kaulich K, Gramatzki D, et al
    Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0890.2017.
    PubMed     Abstract available

  161. ALEXANDER BM, Ba S, Berger MS, Berry DA, et al
    Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0764.2017.
    PubMed     Abstract available

  162. OLMEZ I, Brenneman B, Xiao A, Serbulea V, et al
    Combined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanisms.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0803.2017.
    PubMed     Abstract available

  163. WANG G, Shen J, Sun J, Jiang Z, et al
    Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/beta-catenin Signaling.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0774.2017.
    PubMed     Abstract available

    July 2017
  164. ZHANG CB, Cheng W, Ren X, Wang Z, et al
    Tumor Purity As an Underlying Key Factor in Glioma.
    Clin Cancer Res. 2017 Jul 28. pii: clincanres.2598.2016.
    PubMed     Abstract available

  165. ZHAI L, Ladomersky E, Lauing KL, Wu M, et al
    Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0120.2017.
    PubMed     Abstract available

  166. PATEL SH, Poisson LM, Brat DJ, Zhou Y, et al
    T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower Grade Gliomas: A TCGA/TCIA Project.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0560.2017.
    PubMed     Abstract available

  167. OIZEL K, Chauvin C, Oliver L, Gratas C, et al
    Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.3102.2016.
    PubMed     Abstract available

  168. FAN QW, Nicolaides TP, Weiss WA
    Inhibiting 4EBP1 in glioblastoma.
    Clin Cancer Res. 2017 Jul 10. pii: clincanres.0042.2017.
    PubMed     Abstract available

  169. CANELLA A, Welker AM, Yoo JY, Xu J, et al
    Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3151.2016.
    PubMed     Abstract available

    June 2017
  170. ELLINGSON BM, Gerstner E, Smits M, Huang RY, et al
    Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials.
    Clin Cancer Res. 2017 Jun 27. pii: clincanres.2844.2016.
    PubMed     Abstract available

  171. COOK SANGAR ML, Genovesi LA, Nakamoto MW, Davis MJ, et al
    Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.2943.2016.
    PubMed     Abstract available

    May 2017
  172. GEOERGER B, Bourdeaut F, DuBois SG, Fischer M, et al
    A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Clin Cancer Res. 2017;23:2433-2441.
    PubMed     Abstract available

  173. SLANEY CY, von Scheidt B, Davenport AJ, Beavis PA, et al
    Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Clin Cancer Res. 2017;23:2478-2490.
    PubMed     Abstract available

    April 2017
  174. BAKAS S, Akbari H, Pisapia J, Martinez-Lage M, et al
    In vivo detection of EGFRvIII in glioblastoma via perfusion magnetic resonance imaging signature consistent with deep peritumoral infiltration: the phi index.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1871.2016.
    PubMed     Abstract available

  175. Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Clin Cancer Res. 2017;23:2127.

  176. BATICH KA, Reap EA, Archer GE, Sanchez-Perez L, et al
    Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
    Clin Cancer Res. 2017;23:1898-1909.
    PubMed     Abstract available

  177. BI WL, Horowitz P, Greenwald NF, Abedalthagafi M, et al
    Landscape of Genomic Alterations in Pituitary Adenomas.
    Clin Cancer Res. 2017;23:1841-1851.
    PubMed     Abstract available

    March 2017
  178. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Abstract available

  179. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.

    February 2017
  180. BLOCH O, Lim M, Sughrue ME, Komotar RJ, et al
    Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.1369.2016.
    PubMed     Abstract available

    January 2017
  181. RING EK, Markert JM, Gillespie GY, Friedman GK, et al
    Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
    Clin Cancer Res. 2017;23:342-350.
    PubMed     Abstract available

    December 2016
  182. HOLDHOFF M, Guner G, Rodriguez FJ, Hicks JL, et al
    Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry and in situ hybridization.
    Clin Cancer Res. 2016 Dec 29. pii: clincanres.1490.2016.
    PubMed     Abstract available

  183. PORTNOW J, Synold TW, Badie B, Tirughana R, et al
    Neural stem cell-based anti-cancer gene therapy: a first-in-human study in recurrent high grade glioma patients.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1518.2016.
    PubMed     Abstract available

    November 2016
  184. WANG Z, Hao Y, Zhang CB, Wang Z, et al
    The landscape of viral expression reveals clinically relevant viruses with potential capability of promoting malignancy in lower grade glioma.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.1495.2016.
    PubMed     Abstract available

  185. DADEY DY, Kapoor V, Hoye K, Khudanyan A, et al
    Antibody targeting GRP78 enhances the efficacy of radiation therapy in human glioblastoma and non-small-cell lung cancer cell lines and tumor models.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1935.2016.
    PubMed     Abstract available

    October 2016
  186. ELLIOTT JT, Marra K, Evans LT, Davis SC, et al
    Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma.
    Clin Cancer Res. 2016 Oct 31. pii: clincanres.1400.2016.
    PubMed     Abstract available

  187. KICKINGEREDER P, Gotz M, Muschelli J, Wick A, et al
    Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.
    Clin Cancer Res. 2016.
    PubMed     Abstract available

  188. STEEG PS, Zimmer AS, Gril B
    Therapeutics for Brain Metastases, Version 3.
    Clin Cancer Res. 2016 Oct 10. pii: clincanres.2035.2016.
    PubMed     Abstract available

    September 2016
  189. RAMACHANDRAN M, Yu D, Dyczynski M, Baskaran S, et al
    Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus.
    Clin Cancer Res. 2016 Sep 16. pii: clincanres.0925.2016.
    PubMed     Abstract available

  190. POINTER KB, Clark PA, Eliceiri KW, Salamat MS, et al
    Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients.
    Clin Cancer Res. 2016 Sep 15. pii: clincanres.3169.2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.